FDA Determines Regulatory Review Period for ORENCIA Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ORENCIA, a human biological product, in accordance with federal regulations, following a patent extension application submitted to the Department of Commerce.